Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
Public ClinicalTrials.gov record NCT01868997. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to investigate the efficacy, safety, and tolerability of RV 001 (teprotumumab), a fully human anti-IGF1R antibody, administered q3W for 6 months, in comparison to placebo, in the treatment of participants suffering from active TED. "Funding Source - FDA OOPD"
Study identification
- NCT ID
- NCT01868997
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 88 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2013 (Actual)
- Primary completion
- Mar 2016 (Actual)
- Completion
- Feb 22, 2017 (Actual)
- Last update posted
- Dec 17, 2024
2013 – 2017
United States locations
- U.S. sites
- 11
- U.S. states
- 11
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Jules Stein Eye Institute at UCLA | Los Angeles | California | 90095 | — |
| University of Denver | Aurora | Colorado | 80045 | — |
| Emory University Department of Ophthalmology | Atlanta | Georgia | 30322 | — |
| University of Iowa Hospitals and Clinics, Department of Ophthalmology | Iowa City | Iowa | 52242 | — |
| Kellogg Eye Center at University of Michigan | Ann Arbor | Michigan | 48105 | — |
| Washington University Department of Ophthalmology | St Louis | Missouri | 63110 | — |
| University of Nebraska Medical Center Department of Ophthalmology | Omaha | Nebraska | 68198 | — |
| Casey Eye Institute at Oregon Health and Science University | Portland | Oregon | 97239 | — |
| Hamilton Eye Institute at University of Tennessee | Memphis | Tennessee | 38163 | — |
| Eye Wellness Center | Houston | Texas | 77005 | — |
| Medical College of Wisconsin, The Eye Institute | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01868997, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 17, 2024 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01868997 live on ClinicalTrials.gov.